Clinical Trial Update: Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) [Phase 1, Phase 2]

View source ↗

Summary

MD Anderson is running a Phase 1/2 trial to evaluate the combination of Naxitamab and Sacituzumab Govitecan in metastatic triple-negative breast cancer; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Naxitamab (naxitamab)
• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Triple-Negative Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING